Investors Give Biogened S.A. (WSE:BGD) Shares A 27% Hiding
Dec 06
Have your own idea? Try our Stock Screener
Polish (WIG) Pharma Industry Analysis
UpdatedDec 14, 2024
DataAggregated Company Financials
Companies6
- 7D-4.9%
- 3M-15.8%
- 1Y22.0%
- YTDn/a
Over the last 7 days, the Pharma industry has dropped 7.7%, driven by Celon Pharma declining 8.0%. In contrast, Biogened has gained 5.8%. Over the past 12 months, the industry was up 19%. In the next few years, earnings are forecast to decline by 37% annually.
Industry Valuation and Performance
Has the Polish Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 14 Dec 2024 | zł1.6b | zł360.7m | -zł14,404,163.00 | 41x | -110.6x | 4.4x |
| Mon, 11 Nov 2024 | zł1.7b | zł314.5m | -zł72,767,518.00 | 11.9x | -23.9x | 5.5x |
| Wed, 09 Oct 2024 | zł1.8b | zł314.9m | -zł72,051,939.00 | 10.5x | -25.2x | 5.8x |
| Fri, 06 Sep 2024 | zł1.9b | zł317.3m | -zł60,178,104.00 | 11.6x | -31.5x | 6x |
| Sun, 04 Aug 2024 | zł1.6b | zł310.8m | -zł61,217,640.00 | 11.2x | -26.8x | 5.3x |
| Tue, 02 Jul 2024 | zł1.1b | zł310.8m | -zł61,217,640.00 | 11.9x | -18.4x | 3.6x |
| Thu, 30 May 2024 | zł1.1b | zł312.1m | -zł61,350,052.00 | 9.9x | -18.4x | 3.6x |
| Sat, 27 Apr 2024 | zł1.1b | zł313.6m | -zł43,157,065.00 | 14.6x | -26x | 3.6x |
| Mon, 25 Mar 2024 | zł1.2b | zł311.5m | -zł40,173,065.00 | 18x | -29.2x | 3.8x |
| Wed, 21 Feb 2024 | zł1.2b | zł311.5m | -zł40,173,065.00 | 16x | -30.2x | 3.9x |
| Fri, 19 Jan 2024 | zł1.1b | zł308.7m | -zł39,880,934.00 | 12.8x | -28.8x | 3.7x |
| Sun, 17 Dec 2023 | zł1.2b | zł308.7m | -zł39,880,934.00 | 11.2x | -30.9x | 4x |
| Tue, 14 Nov 2023 | zł1.1b | zł302.0m | -zł44,782,495.00 | 11.9x | -24.6x | 3.6x |
| Thu, 12 Oct 2023 | zł1.1b | zł302.0m | -zł42,933,291.00 | 10.5x | -26.2x | 3.7x |
| Sat, 09 Sep 2023 | zł1.2b | zł287.0m | -zł53,857,118.00 | 11.4x | -22.1x | 4.2x |
| Mon, 07 Aug 2023 | zł1.2b | zł278.4m | -zł53,806,540.00 | 36.6x | -21.9x | 4.2x |
| Wed, 05 Jul 2023 | zł1.1b | zł278.4m | -zł53,806,540.00 | 36.4x | -20.9x | 4x |
| Fri, 02 Jun 2023 | zł1.2b | zł282.1m | -zł51,108,194.00 | 36.7x | -22.7x | 4.1x |
| Sun, 30 Apr 2023 | zł1.1b | zł272.8m | -zł43,525,989.00 | 8.9x | -24.6x | 3.9x |
| Tue, 28 Mar 2023 | zł1.1b | zł273.2m | -zł44,427,333.00 | 8.4x | -24.7x | 4x |
| Thu, 23 Feb 2023 | zł1.1b | zł273.2m | -zł44,427,333.00 | 8.3x | -25.8x | 4.2x |
| Sat, 21 Jan 2023 | zł1.2b | zł270.3m | -zł44,201,704.00 | 7.7x | -26.1x | 4.3x |
| Mon, 19 Dec 2022 | zł993.9m | zł270.3m | -zł44,201,704.00 | 7.7x | -22.5x | 3.7x |
| Wed, 16 Nov 2022 | zł957.4m | zł260.9m | -zł40,809,798.00 | 8.4x | -23.5x | 3.7x |
| Fri, 14 Oct 2022 | zł851.1m | zł260.9m | -zł40,391,998.00 | 9.7x | -21.1x | 3.3x |
| Sun, 11 Sep 2022 | zł1.1b | zł265.6m | -zł29,272,739.00 | 9.7x | -35.9x | 4x |
| Tue, 09 Aug 2022 | zł1.2b | zł264.2m | -zł29,985,890.00 | 12.3x | -39.4x | 4.5x |
| Thu, 07 Jul 2022 | zł977.8m | zł264.2m | -zł29,985,890.00 | 10.5x | -32.6x | 3.7x |
| Sat, 04 Jun 2022 | zł1.3b | zł264.2m | -zł29,985,890.00 | 12x | -44.9x | 5.1x |
| Mon, 02 May 2022 | zł1.6b | zł235.3m | -zł1,158,483.00 | 56.8x | -1352.8x | 6.7x |
| Wed, 30 Mar 2022 | zł1.8b | zł358.1m | zł72.0m | 14.4x | 25.2x | 5.1x |
| Fri, 25 Feb 2022 | zł1.6b | zł358.1m | zł72.0m | 12.6x | 21.8x | 4.4x |
| Sun, 23 Jan 2022 | zł2.2b | zł350.0m | zł71.4m | 16x | 30.6x | 6.2x |
| Tue, 21 Dec 2021 | zł2.3b | zł350.0m | zł71.4m | 13.1x | 32.2x | 6.6x |
Price to Earnings Ratio
32.2x
Current Industry PE
- Investors are relatively neutral on the Polish Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 4.5x.
Past Earnings Growth
- Total earnings for the Pharmaceuticals industry have declined over the last three years, with the industry now making a loss overall.
- Meanwhile revenues have remained mostly flat.
- This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Comparison
How does Polish Pharma compare with similar industries?
| PL Market | -1.18% | |
| Healthcare | -0.75% | |
| Pharma | -4.86% | |
| Pharma | -4.86% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| BGD Biogened | zł20.00 | 5.8% +zł2.7m | 15.6% | PE10.1x | |
| GRZ Green Zebras Spolka Akcyjna | zł13.50 | 1.2% +zł212.5k | n/a | n/a |